Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)
Conditions
Interventions
Pemigatinib
Locations
120
United States
Anchorage, Alaska, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Tucson, Arizona, United States
Orange, California, United States
San Francisco, California, United States
Start Date
January 16, 2017
Primary Completion Date
February 1, 2022
Completion Date
February 1, 2022
Last Updated
August 14, 2025
NCT04891289
NCT05969860
NCT06503146
NCT07486713
NCT07282912
NCT05497531
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions